Cell and Gene Therapy Development
Assess Critical Quality Attributes (CQA) for cell and gene therapies — identity, biosafety, and potency — using NGS data analysis with Genedata Selector®. Deliver safe and efficacious therapies to patients faster.
Streamline CGT Manufacturing Processes
Genedata Selector enables automation and standardization of NGS-based cell and gene therapy assays.
This out-of-the-box support includes safety assays, sequence characterization, and potency assessment.
Ensure Mycoplasma-Free CGT
When used to analyze NGS data, Genedata Selector provides a comprehensive solution for detecting adventitious agents, such as mycoplasma, throughout the CGT development process.
Learn in 3 minutes how our platform helps to ensure mycoplasma-free cell and gene therapy products:
Confirm the Integrity of Viral Vectors
Actionable go/no-go signals provided by Genedata Selector leads to faster and better informed decisions regarding sequence integrity of viral vectors.
Learn in 3 minutes how to streamline decision-making for safe CGT development:
Assess Potency with scRNAseq Analysis
Genedata Selector supports single cell RNAseq data analyses to streamline your decision-making using the informative and interactive data display.
Learn in 3 minutes how to determine identity and potency of your cells' populations: